Dyne Therapeutics Inc represents a set of core values and corporate philosophy that sets it apart in the industry. The company prioritizes innovation, excellence, and patient-centricity in all aspects of its operations. Dyne Therapeutics is committed to developing life-changing therapies using its proprietary FORCE™ platform to treat serious muscle diseases. With an unwavering dedication to scientific rigor and collaboration, Dyne Therapeutics aims to redefine the treatment landscape for patients in need. By combining cutting-edge technology with a focus on patient outcomes, Dyne Therapeutics strives to make a meaningful impact in the lives of people affected by muscle diseases.

Dyne Therapeutics Inc is primarily present in the United States.

As of October 2021, Dyne Therapeutics Inc has achieved significant milestones. The company successfully completed its initial public offering (IPO) in May 2020, raising approximately $201 million. Dyne Therapeutics also established strategic collaborations with leading organizations like Roche, Novartis, Sanofi, and Sarepta Therapeutics. They have made remarkable progress in their research and development efforts, with a focus on advancing their proprietary FORCE platform for treating muscle diseases. Dyne Therapeutics has received notable recognition for its innovative approach and has attracted investment from prominent venture capital firms. The company continues to make strides towards developing novel therapies for patients with serious muscle disorders.

Dyne Therapeutics Inc is a leading biotechnology company that specializes in developing innovative therapies for patients suffering from muscle diseases. Established in [year], Dyne Therapeutics has rapidly grown to become a prominent player in the field. The company's dedicated team of experts combines their extensive knowledge of muscle biology with advanced technologies to create transformative treatments. Dyne Therapeutics focuses on developing targeted therapies that aim to restore muscle function and improve patients' quality of life. With a strong commitment to research and development, Dyne Therapeutics is dedicated to making a meaningful impact on the lives of individuals living with muscle diseases.

The main competitors of Dyne Therapeutics Inc in the market include companies such as Sarepta Therapeutics, Wave Life Sciences, and Solid Biosciences.

Dyne Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Dyne Therapeutics Inc revolves around developing life-transforming therapies for patients with serious muscle diseases. By harnessing their proprietary force-based platform, Dyne Therapeutics aims to overcome the limitations of traditional approaches and enable the delivery of nucleic acids, such as oligonucleotides, to muscle tissues. This innovative approach holds the potential to address a wide range of muscle diseases. Dyne Therapeutics Inc is dedicated to pushing the boundaries of science and leveraging its expertise to create impactful treatments for patients in need.

Dyne Therapeutics KGV yra −6,79.

Dyne Therapeutics KUV yra 0.

AlleAktien kokybės įvertis Dyne Therapeutics yra 2/10.

Pajamos šiuo metu negali būti apskaičiuotos Dyne Therapeutics.

tikėtina Dyne Therapeutics pelnas yra −304,21 mln. USD.

Dyne Therapeutics is a biotechnology company specializing in the development of new therapies for inherited muscular diseases. The company is based in Waltham, Massachusetts, USA. They focus on researching, developing, and marketing innovative therapies for diseases caused by genetic defects. One of their main areas of focus is the development of antisense oligonucleotides (ASOs), which are short nucleotide sequences that can target specific RNA molecules and influence gene expression. They have also developed a proprietary ASO technology platform that allows them to deliver ASOs to specific tissues and cells relevant to certain genetic diseases. They are developing therapeutics for Duchenne muscular dystrophy (DMD) and other inherited muscular diseases. They are also developing therapies aimed at stabilizing and increasing the production of important structural and functional proteins. An example of this is their innovative drug, Dyn101, which aims to replace or enhance the missing protein in DMD patients. The company's products are still in the development phase and are not currently commercially available. They are working on a patented ASO technology platform and have several promising drug candidates in clinical development stages. They use both internal research and development as well as external partnerships to expand their therapy options. They collaborate with renowned research institutions and universities to discover innovative new therapies and technologies and validate their clinical efficacy and safety. Their business model is focused on long-term growth and success. They are dedicated to developing innovative therapies for inherited muscular diseases and expect to achieve positive clinical results in the coming years, which will allow them to apply for therapeutic approval. In summary, Dyne Therapeutics is a biotechnology company specialized in developing therapeutics based on antisense oligonucleotides and other innovative technologies to treat inherited muscular diseases. They aim to better meet the needs of patients affected by these diseases and establish themselves as a leading company in this field through continuous research and development of new products and technologies.

Dyne Therapeutics moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Dyne Therapeutics arba įmonė dividendų nemoka.

Dyne Therapeutics ISIN yra US26818M1080.

Dyne Therapeutics WKN yra A2QB6B.

Dyne Therapeutics akcijų simbolis yra DYN.

Per paskutinius 12 mėnesių Dyne Therapeutics išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Dyne Therapeutics tikėtina išmokės dividendus, kurie sudarys 0 USD.

Dyne Therapeutics šiuo metu yra dydžio dividendų grąža.

Dyne Therapeutics moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Dyne Therapeutics per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Dyne Therapeutics priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Dyne Therapeutics dividendą nuo 2024-09-27, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-27.

Paskutinės dividendų išmokėjimas įvyko 2024-09-27.

2023 metais Dyne Therapeutics išmokėjo 0 USD dividendų.

Dyne Therapeutics dividendai yra mokami USD.